Added to YB: 2026-09-08
Pitch date: 2026-09-05
IDXG [neutral]
Interpace Biosciences, Inc.
Author Info
I research and share thesis-driven ideas on potential healthcare multibaggers. Sign up for the newsletter.
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States.
Market Cap
$38.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.04
P/E
1.52
EV/Sales
1.01
Sector
Health Care Providers and Services
Category
special_situation
This Week in Healthcare - Issue #1 - Interpace Biosciences Inc
IDXG (update): Interpace Biosciences completed a 1-for-5 reverse stock split on August 27, reducing shares outstanding from approximately 27.7 million to 5.5 million. The action is intended to satisfy Nasdaq’s minimum bid-price requirement ahead of a proposed uplisting from OTCID, but other conditions remain, including a $15 million market value of unrestricted publicly held shares, and completion is not guaranteed.
Read full article (1 min)